icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
u3AaZKPQNusRxvzw
Listen
